December 5, 2019Open Access

Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck

Key Points

Key points are not available for this paper at this time.

Abstract

This study's findings suggest that immunosuppression is independently associated with a worse outcome in cSCC, with a 2.32 times increased risk of disease-specific death after adjusting for age, history of skin cancer, recurrent or persistent disease status, disease stage, and treatment.

Perguntar à IA

Bookmark

View Full Paper

Cite This Study

Tam et al. (Thu,) studied this question.

synapsesocial.com/papers/69d88908c025a7c015bedfb1 https://doi.org/https://doi.org/10.1001/jamaoto.2019.3751

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial2016 · 1,741 citations
2A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck2012 · 175 citations
3Histologic Features in Primary Cutaneous Squamous Cell Carcinomas in Immunocompromised Patients Focusing on Organ Transplant Patients2004 · 13 citations
4A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor2015 · 87 citations
5Histologic Features in Primary Cutaneous Squamous Cell Carcinomas in Immunocompromised Patients Focusing on Organ Transplant Patients2004 · 72 citations

Perguntar à IA

Bookmark

View Full Paper